statins + ezetimibe + PCSK9 inhibitor

"Statins + ezetimibe + PCSK9 inhibitor" is an intensive lipid-lowering combination regimen utilized in clinical research to achieve maximal reduction of LDL cholesterol (LDL-C). This triple-therapy approach targets three distinct pathways of cholesterol metabolism: **statins** (e.g., atorvastatin, rosuvastatin) inhibit HMG-CoA reductase to decrease hepatic cholesterol synthesis; **ezetimibe** inhibits the NPC1L1 transporter to block intestinal cholesterol absorption; and **PCSK9 inhibitors** (e.g., alirocumab, evolocumab, or inclisiran) prevent the degradation of LDL receptors, thereby enhancing the liver's ability to clear LDL-C from the circulation. In the context of the University of Colorado, Denver's clinical trial (NCT05554276), this regimen is being evaluated as "aggressive lipid lowering therapy" to mitigate cardiovascular risk and plaque progression in melanoma patients receiving immune checkpoint inhibitors (ICIs), who may be at increased risk for atherosclerotic plaque destabilization.

Other names

aggressive lipid lowering therapytriple lipid-lowering therapy